

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**April 15, 2025**

---

**I Continuing Review**

**10466**, A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer (Version Date 03/03/25)

---

**II Continuing Review**

**NRG-GY031**, A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer (Version Date 09/04/24)

---

**III Continuing Review**

**10525**, A Phase 1b Trial of ZEN003694 (ZEN-3694) with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer (Version Date 10/03/24)

---

**IV Continuing Review**

**10614**, A Phase 2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers (Version Date 09/06/24)

---